From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 3.11
Pain Relevance 0.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (FLT3)
Anatomy Link Frequency
internal 1
FLT3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 5 57.04 Quite High
headache 5 11.88 Low Low
Pain 3 11.48 Low Low
dexamethasone 11 5.00 Very Low Very Low Very Low
peripheral neuropathy 3 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
Potency 2 5.00 Very Low Very Low Very Low
antagonist 2 5.00 Very Low Very Low Very Low
fibrosis 1 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 25 97.82 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 85 96.08 Very High Very High Very High
Myelofibrosis 11 95.12 Very High Very High Very High
Congenital Anomalies 1 89.28 High High
Vomiting 17 88.08 High High
Exanthema 7 87.64 High High
Diarrhoea 16 87.40 High High
Myelodysplastic Syndromes 11 86.76 High High
Disease 28 84.92 Quite High
Appetite Loss 4 76.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Vatalanib decreased VEGF levels and VEGFR phosphorylation in AML cells, which showed FLT3 internal tandem reduplications/mutations (ITD), raising the question of the actual targeted tyrosine kinase (VEGFR or flt3).
Regulation (targeted) of flt3 in internal associated with myeloid leukemia
1) Confidence 0.35 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 1.80 Pain Relevance 0
Sunitinib is an orally-active small molecule tyrosine kinase inhibitor that acts on multiple targets including VEGFR, PDGFR, c-kit and Flt-3.[46] In a phase II, open-label, multicenter study, sunitinib was evaluated as monotherapy in patients with MBC. 64 patients previously treated with an anthracycline and a taxane received sunitinib 50 mg daily in six week cycles, and results showed that 7 patients achieved a partial response with a median duration of 19 weeks giving an ORR of 11%. 3 patients achieved stable disease for greater than 6 months.
Regulation (acts) of Flt-3 associated with disease and advanced or metastatic breast cancer
2) Confidence 0.03 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.31 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools